Dmitry Balyasny’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Dmitry Balyasny’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-90,954	Closed	-$80.6K	–	3391
2022 Q4	$80.6K	Buy	90,954 +54,860	+152%	+$72.8K	﹤0.01%	2277
2022 Q3	$57K	Sell	36,094 -25,352	-41%	-$57.5K	﹤0.01%	2463
2022 Q2	$124K	Buy	+61,446	New	+$106K	﹤0.01%	2258
2022 Q1	–	Sell	-13,805	Closed	-$64K	–	3014
2021 Q4	$64K	Buy	+13,805	New	+$85.7K	﹤0.01%	2034
2021 Q2	–	Sell	-15,266	Closed	-$126K	–	2529
2021 Q1	$126K	Sell	15,266 -5,864	-28%	-$61.9K	﹤0.01%	1618
2020 Q4	$144K	Buy	+21,130	New	+$170K	﹤0.01%	1241
2018 Q4	–	Sell	-103,252	Closed	-$454K	–	1869
2018 Q3	$454K	Buy	+103,252	New	+$572K	﹤0.01%	1409

Other funds holding SRNE

Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

OFA

Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return

CGA

Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return

LCM

Lattice Capital Management Kirkland, Washington $49.5M AUM 28.58% 1-Year Est. Return

STB

S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return

GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return

HFRG

Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return

VFA

Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return

GBWM

Granite Bay Wealth Management Portsmouth, New Hampshire $1.09B AUM 22.93% 1-Year Est. Return

Dmitry Balyasny's SRNE Position: Q1 2023 in Review

Dmitry Balyasny sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 90,954 shares — an estimated $80.6K sold.

Dmitry Balyasny first reported a position in SRNE in Q3 2018 and held it in 7 quarters. The position peaked at $454K in Q3 2018. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

Dmitry Balyasny reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
Dmitry Balyasny sold 90,954 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $80.6K.
Dmitry Balyasny first reported a position in Sorrento Therapeutics, Inc. in Q3 2018 and held it in 7 quarters.
Dmitry Balyasny's Sorrento Therapeutics, Inc. position peaked at $454K in Q3 2018.
34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Balyasny Asset Management's 13F filing for Q1 2023, filed 15 May 2023.